Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.63 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7462472 | 0.88 | PTPN1 (0.60) | PTPN1ACKR3ALDH1A1MEN1KMT2A | |
| SCHEMBL30034590 | 0.87 | PTPN1 (0.63) | PTPN1ACKR3ALDH1A1MEN1KMT2A | |
| SCHEMBL4808309 | 0.86 | PTPN1 (0.61) | PTPN1ACKR3ALDH1A1MEN1KMT2A | |
| SCHEMBL30791550 | 0.86 | PTPN1 (0.61) | PTPN1ACKR3ALDH1A1MEN1KMT2A | |
| SCHEMBL951041 | 0.86 | PTPN1 (0.61) | PTPN1ACKR3ALDH1A1MEN1KMT2A | |
| SCHEMBL2065774 | 0.86 | PTPN1 (0.61) | PTPN1ACKR3ALDH1A1MEN1KMT2A | |
| SCHEMBL4156900 | 0.85 | ALDH1A1 (0.67) | PTPN1ACKR3ALDH1A1MEN1KMT2A | |
| SCHEMBL2828269 | 0.84 | ALDH1A1 (0.67) | ALDH1A1MEN1KMT2AMAPTTSHR | |
| SCHEMBL2828273 | 0.84 | ALDH1A1 (0.67) | ALDH1A1MEN1KMT2AMAPTTSHR | |
| SCHEMBL9781025 | 0.83 | ALDH1A1 (0.59) | PTPN1ACKR3ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879858-A2 | PROCESSES FOR PREPARING BIARYL UREAS AND ANALOGS THEREOF | Vertex Pharmaceuticals, Inc. (US) | 2008-01-23 | — | — | EP | claimed |
| WO-2006122072-A2 | PROCESSES FOR PREPARING BIARYL UREAS AND ANALOGS THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-11-16 | — | — | WO | claimed |
| EP-1673337-A2 | ARYLALKYLCARBAMATE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2006-06-28 | — | — | EP | claimed |
| WO-2005033066-A2 | ARYLALKYLCARBAMATE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2005-04-14 | — | — | WO | claimed |
| WO-2023227125-A1 | NEW FUSED-HETEROCYCLIC COMPOUND AS CDK INHIBITOR AND USE THEREOF | 杭州德睿智药科技有限公司 | 2023-11-30 | — | — | WO | disclosed |
| CN-116710116-A | Beta-sheet femoral bridge peptide | Ｘｅｎｏ－Ｉｎｔｅｒｆａｃｅ株式会社 | 2023-09-05 | — | — | CN | disclosed |
| CN-114146056-A | Modular compositions for scavenging soluble biomolecules and methods related thereto | 纳米提克斯有限责任公司 | 2022-03-08 | — | — | CN | disclosed |
| CN-110662736-A | Process for producing amide compound | 学校法人中部大学 | 2020-01-07 | — | — | CN | disclosed |
| US-20190210992-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE (US) | 2019-07-11 | — | — | US | disclosed |
| US-10287264-B2 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | TEXAS HEART INSTITUTE (US) | 2019-05-14 | — | — | US | disclosed |
| EP-3388429-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | Texas Heart Institute (US) | 2018-10-17 | — | — | EP | disclosed |
| EP-2640721-B1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INST (US) | 2018-06-06 | — | — | EP | disclosed |
| WO-2012068251-A2 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE (US) | 2012-05-24 | — | — | WO | disclosed |
| EP-2399921-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-12-28 | — | — | EP | disclosed |
| EP-1972616-A1 | Derivatives of arylalkylcarbamates, process for their preparation and therapeutic application thereof | Sanofi-Aventis (FR) | 2008-09-24 | — | — | EP | disclosed |
| CN-101175718-A | Processes for preparing biaryl ureas and analogs thereof | VERTEX PHARMA (US) | 2008-05-07 | — | — | CN | disclosed |
| EP-1879858-A2 | PROCESSES FOR PREPARING BIARYL UREAS AND ANALOGS THEREOF | Vertex Pharmaceuticals, Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006122072-A2 | PROCESSES FOR PREPARING BIARYL UREAS AND ANALOGS THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-11-16 | — | — | WO | disclosed |
| EP-1673337-A2 | ARYLALKYLCARBAMATE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005033066-A2 | ARYLALKYLCARBAMATE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210992-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | PTPN1 3458/4885ACKR3 94/4885ALDH1A1 725/4885 |
| US-10287264-B2 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | ITGB7, ITGAL, ITGB1 | PTPN1 3413/4885ACKR3 100/4885ALDH1A1 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.